Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Eiermann, W ^a  

^a Frauenklinik vom Roten Kreuz   (Germany)

Author keywords

First line treatment; HER2; Herceptin; Metastatic breast cancer; Survival; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; METASTASIS; MULTICENTER STUDY; ONCOGENE NEU; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME;

EID: 0034873390     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S57     Document Type: Article

References (19)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. The biology of erbB-2/neu/HER-2 and its role in cancer
3. 3 cells
4. 3 cells
5. 3 cells
6. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
7. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
8. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
9. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
10. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer treatment
11. Addition of Herceptin® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational trial
12. Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
13. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)
14. Tolerability in patients receiving trastuzumab with or without chemotherapy
15. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiamminedichloroplatinum against human breast and ovarian tumor cell lines
16. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth
17. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
18. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
19. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumor growth